Companies › BioCardia
1 active drug program in 1 registered trial: 1 Phase 1; Cardiovascular; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| CardiALLO™ Human Allogenic Culture-expanded Bone marrow-derived Mesenchymal Stem Allogenic bone marrow-derived mesenchymal stem cells with immunomodulatory and regenerativ | – | Phase 1 | Heart Failure, Systolic | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05925608 | CardiALLO™ Human Allogenic Culture-expanded Bone marrow-derived Mesenchymal Stem | Phase 1 | Heart Failure, Systolic | Cardiovascular | Dec 2026 |
Cash of $4m on 2026-06-30; operating cash outflow about $7m a year; runway about 7 months at that burn, to Feb 2027
Press releases filed as 8-K in the last year:
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.